结直肠癌中的TRIM蛋白：TRIM8作为化疗耐药中一个有前景的治疗靶点
TRIM Proteins in Colorectal Cancer: TRIM8 as a Promising Therapeutic Target in Chemo Resistance.
作者信息
Marzano Flaviana, Caratozzolo Mariano Francesco, Pesole Graziano, Sbisà Elisabetta, Tullo Apollonia
机构信息
Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies, National Research Council, CNR, 70126 Bari, Italy.
Department of Biosciences, Biotechnology and Biopharmaceutics, University of Bari, "Aldo Moro", 70125 Bari, Italy.
出版信息
Biomedicines. 2021 Feb 27;9(3):241. doi: 10.3390/biomedicines9030241.
Colorectal cancer (CRC) represents one of the most widespread forms of cancer in the population and, as all malignant tumors, often develops resistance to chemotherapies with consequent tumor growth and spreading leading to the patient's premature death. For this reason, a great challenge is to identify new therapeutic targets, able to restore the drugs sensitivity of cancer cells. In this review, we discuss the role of TRIpartite Motifs (TRIM) proteins in cancers and in CRC chemoresistance, focusing on the tumor-suppressor role of TRIM8 protein in the reactivation of the CRC cells sensitivity to drugs currently used in the clinical practice. Since the restoration of TRIM8 protein levels in CRC cells recovers chemotherapy response, it may represent a new promising therapeutic target in the treatment of CRC
结直肠癌（CRC）是人群中最常见的癌症形式之一，与所有恶性肿瘤一样，它常常对化疗产生耐药性，进而导致肿瘤生长和扩散，最终致使患者过早死亡。因此，识别能够恢复癌细胞对药物敏感性的新治疗靶点是一项巨大挑战。在本综述中，我们讨论了TRIpartite Motifs（TRIM）蛋白在癌症和CRC化疗耐药中的作用，重点关注TRIM8蛋白在恢复CRC细胞对目前临床实践中使用药物的敏感性方面的肿瘤抑制作用。由于恢复CRC细胞中TRIM8蛋白水平可恢复化疗反应，它可能是CRC治疗中一个新的有前景的治疗靶点。
Zotero 插件